335 related articles for article (PubMed ID: 31208414)
1. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
Kaul U; Parmar D; Manjunath K; Shah M; Parmar K; Patil KP; Jaiswal A
Cardiovasc Diabetol; 2019 Jun; 18(1):80. PubMed ID: 31208414
[TBL] [Abstract][Full Text] [Related]
2. Saroglitazar for the treatment of dyslipidemia in diabetic patients.
Joshi SR
Expert Opin Pharmacother; 2015 Mar; 16(4):597-606. PubMed ID: 25674933
[TBL] [Abstract][Full Text] [Related]
3. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
[TBL] [Abstract][Full Text] [Related]
4. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
[TBL] [Abstract][Full Text] [Related]
5. Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
Goyal O; Nohria S; Goyal P; Kaur J; Sharma S; Sood A; Chhina RS
Sci Rep; 2020 Dec; 10(1):21117. PubMed ID: 33273703
[TBL] [Abstract][Full Text] [Related]
6. Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.
Chatterjee S; Majumder A; Ray S
Sci Rep; 2015 Jan; 5():7706. PubMed ID: 25573251
[TBL] [Abstract][Full Text] [Related]
7. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Gawrieh S; Noureddin M; Loo N; Mohseni R; Awasty V; Cusi K; Kowdley KV; Lai M; Schiff E; Parmar D; Patel P; Chalasani N
Hepatology; 2021 Oct; 74(4):1809-1824. PubMed ID: 33811367
[TBL] [Abstract][Full Text] [Related]
8. Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients.
Shetty SR; Kumar S; Mathur RP; Sharma KH; Jaiswal AD
Indian Heart J; 2015; 67(1):23-6. PubMed ID: 25820046
[TBL] [Abstract][Full Text] [Related]
9. Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.
Jain N; Bhansali S; Kurpad AV; Hawkins M; Sharma A; Kaur S; Rastogi A; Bhansali A
Sci Rep; 2019 Dec; 9(1):19017. PubMed ID: 31831868
[TBL] [Abstract][Full Text] [Related]
10. A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia.
Balakumar P; Mahadevan N; Sambathkumar R
Curr Mol Pharmacol; 2019; 12(3):195-201. PubMed ID: 30636619
[TBL] [Abstract][Full Text] [Related]
11. Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
Rastogi A; Dunbar RL; Thacker HP; Bhatt J; Parmar K; Parmar DV
Acta Diabetol; 2020 Jul; 57(7):809-818. PubMed ID: 32030508
[TBL] [Abstract][Full Text] [Related]
12. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.
Rajesh NA; Drishya L; Ambati MMR; Narayanan AL; Alex M; R KK; Abraham JJ; Vijayakumar TM
J Clin Exp Hepatol; 2022; 12(1):61-67. PubMed ID: 35068786
[TBL] [Abstract][Full Text] [Related]
14. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
[TBL] [Abstract][Full Text] [Related]
15. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
Goldstein BJ; Rosenstock J; Anzalone D; Tou C; Ohman KP
Curr Med Res Opin; 2006 Dec; 22(12):2575-90. PubMed ID: 17166340
[TBL] [Abstract][Full Text] [Related]
16. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD.
Ezhilarasan D
Metabolism; 2024 Jun; 155():155912. PubMed ID: 38609038
[TBL] [Abstract][Full Text] [Related]
18. P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.
Chen W; Zhou XB; Liu HY; Xu C; Wang LL; Li S
Br J Pharmacol; 2009 Jul; 157(5):724-35. PubMed ID: 19422369
[TBL] [Abstract][Full Text] [Related]
19. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
Kumar DP; Caffrey R; Marioneaux J; Santhekadur PK; Bhat M; Alonso C; Koduru SV; Philip B; Jain MR; Giri SR; Bedossa P; Sanyal AJ
Sci Rep; 2020 Jun; 10(1):9330. PubMed ID: 32518275
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).
Jani RH; Pai V; Jha P; Jariwala G; Mukhopadhyay S; Bhansali A; Joshi S
Diabetes Technol Ther; 2014 Feb; 16(2):63-71. PubMed ID: 24138536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
